Similar articles for PMID: 29706099

Year	Number of Results
1999	1
2002	1
2006	1
2008	3
2009	2
2010	2
2011	2
2012	6
2013	5
2014	3
2015	12
2016	17
2017	10
2018	12
2019	4
2020	6
2021	9
2022	8
2023	5
2024	0

1

Economic evaluation of human urinary kallindinogenase for patients with acute ischemic stroke in China.

Lin Z, Rao X, Zhang Z, Xuan J. Lin Z, et al. J Med Econ. 2018 Aug;21(8):778-783. doi: 10.1080/13696998.2018.1470977. Epub 2018 May 22. J Med Econ. 2018. PMID: 29706099 Free article. Clinical Trial.

2

Efficacy and Safety of Dl-3-n-Butylphthalide Combined With Human Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke.

Zhang Y, Zhou F, Li H, Lei J, Mo Z, Li G, Wang J. Zhang Y, et al. Clin Neuropharmacol. 2023 Mar-Apr 01;46(2):60-65. doi: 10.1097/WNF.0000000000000543. Epub 2023 Feb 15. Clin Neuropharmacol. 2023. PMID: 36790373

3

Human urinary kallidinogenase or edaravone combined with butylphthalide in the treatment of acute ischemic stroke.

Qian Y, Lyu Y, Jiang M, Tang B, Nie T, Lu S. Qian Y, et al. Brain Behav. 2019 Dec;9(12):e01438. doi: 10.1002/brb3.1438. Epub 2019 Oct 22. Brain Behav. 2019. PMID: 31638334 Free PMC article. Clinical Trial.

4

Human urinary kallindinogenase therapy for acute ischemic stroke according to Chinese ischemic stroke subclassification: Clinical efficacy and risk factors.

Chen SQ, Mao DY, Wei DC, He WZ. Chen SQ, et al. Brain Behav. 2020 Jan;10(1):e01461. doi: 10.1002/brb3.1461. Epub 2019 Dec 2. Brain Behav. 2020. PMID: 31793238 Free PMC article.

5

Re-evaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK): Protocol for an Open-Label, Single-Arm, Multicenter Phase IV Trial for the Treatment of Acute Ischemic Stroke in Chinese Patients.

Ni J, Qu J, Yao M, Zhang Z, Zhong X, Cui L; RESK investigators. Ni J, et al. Transl Stroke Res. 2017 Aug;8(4):341-346. doi: 10.1007/s12975-017-0527-5. Epub 2017 Mar 6. Transl Stroke Res. 2017. PMID: 28265861 Clinical Trial.

6

Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China.

Zhao J, Jiang K, Li Q, Zhang Y, Cheng Y, Lin Z, Xuan J. Zhao J, et al. J Med Econ. 2019 May;22(5):439-446. doi: 10.1080/13696998.2019.1580714. Epub 2019 Mar 5. J Med Econ. 2019. PMID: 30732487 Free article.

7

Chinese acute ischemic stroke treatment outcome registry (CASTOR): protocol for a prospective registry study on patterns of real-world treatment of acute ischemic stroke in China.

Sun W, Ou Q, Zhang Z, Qu J, Huang Y. Sun W, et al. BMC Complement Altern Med. 2017 Jul 6;17(1):357. doi: 10.1186/s12906-017-1863-4. BMC Complement Altern Med. 2017. PMID: 28683732 Free PMC article.

8

N-Butylphthalide vs. Human Urinary Kallidinogenase for the Treatment of Acute Ischemic Stroke: Functional Outcome and Impact on Serum VEGF and TNF-α Expressions.

Guo Y, Abdoulaye IA, Liu F, Wang J, Tian X, Yu D, Le K. Guo Y, et al. Ann Clin Lab Sci. 2021 Jul;51(4):503-511. Ann Clin Lab Sci. 2021. PMID: 34452888

9

Cost-Effectiveness of Low-Dose Compared to Standard-Dose Alteplase for Acute Ischemic Stroke in China: A Within-Trial Economic Evaluation of the ENCHANTED Study.

Si L, Chen X, Ouyang M, Wang X, Chen G, Cao YJ, Wu G, Zhang J, Zhang J, Liu Y, Zhang S, Song L, Delcourt C, Arima H, Wang L, Lung T, Chen M, Anderson CS, Jan S; ENCHANTED Investigators. Si L, et al. Cerebrovasc Dis. 2023;52(2):145-152. doi: 10.1159/000525869. Epub 2022 Aug 31. Cerebrovasc Dis. 2023. PMID: 36044836 Free article.

10

Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China.

Peng Z, Hou X, Huang Y, Xie T, Hua X. Peng Z, et al. BMC Cancer. 2020 Oct 13;20(1):990. doi: 10.1186/s12885-020-07486-w. BMC Cancer. 2020. PMID: 33050905 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

96 results

Results by year